Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.

Ardelyx (ARDX) announced the approval of a New Drug Application, NDA, by China’s Center for Drug Evaluation of the National Medical Products Administration for tenapanor to control serum ...

Antengene’s new drug application (NDA) for Xpovio (selinexor) has gained approval from the Indonesia National Agency of Drug ...

Discover how outsourcing regulatory submission content development improves efficiency and ensures compliance.

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...

The NDA approval for tenapanor in China supports Ardelyx's goal of addressing significant unmet medical needs in patients with chronic kidney disease. The approval triggers a $5 million milestone ...

Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA. Click here to find ...

Andhra Pradesh SIPB approves ₹3.10 lakh crore investments, targeting 3.12 lakh jobs, including major projects by ...

The FDA is reviewing the supplemental NDA for cabozantinib in adults with ... The Company is seeking approval for acute treatment of migraine with or without aura.